<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pharmateca</journal-id><journal-title-group><journal-title xml:lang="en">Pharmateca</journal-title><trans-title-group xml:lang="ru"><trans-title>Фарматека</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2073-4034</issn><issn publication-format="electronic">2414-9128</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">625942</article-id><article-id pub-id-type="doi">10.18565/pharmateca.2023.13.64-70</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Species diversity of the vaginal microbiota and local immune status in patients with recurrent bacterial vaginosis</article-title><trans-title-group xml:lang="ru"><trans-title>Видовое разнообразие микробиоты влагалища и локальный иммунный статус у пациенток с рецидивирующим бактериальным вагинозом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9334-9978</contrib-id><name-alternatives><name xml:lang="en"><surname>Aisaeva</surname><given-names>B. M.</given-names></name><name xml:lang="ru"><surname>Айсаева</surname><given-names>Б. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Teaching Assistant at the Department of Medical Simulation and Educational Practice</p></bio><bio xml:lang="ru"><p>ассистент кафедры медицинской симуляции и учебной практики</p></bio><email>aysaevabakhu1995@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9524-8962</contrib-id><name-alternatives><name xml:lang="en"><surname>Dikke</surname><given-names>G. B.</given-names></name><name xml:lang="ru"><surname>Дикке</surname><given-names>Г. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>pharmateca@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7729-1606</contrib-id><name-alternatives><name xml:lang="en"><surname>Abusueva</surname><given-names>Z. A.</given-names></name><name xml:lang="ru"><surname>Абусуева</surname><given-names>З. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>pharmateca@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-9947-0815</contrib-id><name-alternatives><name xml:lang="en"><surname>Gitinova</surname><given-names>P. Zh.</given-names></name><name xml:lang="ru"><surname>Гитинова</surname><given-names>П. Ж.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>pharmateca@yandex.ru</email><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Dagestan State Medical University</institution></aff><aff><institution xml:lang="ru">Дагестанский государственный медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">F.I. Inozemtsev Academy of Medical Education</institution></aff><aff><institution xml:lang="ru">Академия медицинского образования им. Ф.И. Иноземцева</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Makhachkala Maternity Hospital № 2</institution></aff><aff><institution xml:lang="ru">Махачкалинский родильный дом № 2</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Serpukhov City Hospital n.a. N.A. Semashko</institution></aff><aff><institution xml:lang="ru">Серпуховская городская больница им. Н.А. Семашко</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-12-04" publication-format="electronic"><day>04</day><month>12</month><year>2023</year></pub-date><volume>30</volume><issue>13</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>64</fpage><lpage>70</lpage><history><date date-type="received" iso-8601-date="2024-01-23"><day>23</day><month>01</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-01-23"><day>23</day><month>01</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, ООО «Бионика Медиа»</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/2073-4034/article/view/625942">https://journals.eco-vector.com/2073-4034/article/view/625942</self-uri><abstract xml:lang="en"><p><bold>Background.</bold> Currently, there is a high frequency of relapses of bacterial vaginosis (BV) more than 50% within 3–6 months and from 69 to 80% of follow-up within 12 months after treatment.</p> <p><bold>Objective.</bold> Evaluation of the features of nonspecific vaginal protection in patients with recurrent BV (RBV) infected with the herpes simplex virus (HSV).</p> <p><bold>Methods.</bold> The study included 100 patients, divided into 2 groups: I (n=80) – with a clinical diagnosis of RBV and HSV, II (n=20) – conditionally healthy. The bacterial composition in vaginal discharge was determined using real-time polymerase chain reaction and the content of interleukin-1β (IL-1β), IL-2, -6, -8, interferon γ, tumor necrosis factor α (TNF-α), IL4, -10 in vaginal secretions – by enzyme immunoassay.</p> <p><bold>Results.</bold> Gardnerella vaginalis, Prevotella bivia and Atopobium vaginae were most often isolated (83.8%); Megasphaera spp., Mobiluncus spp. (66.3%) and Staphylococcus spp. (32.5%) were found in most patients, other BV-associated bacteria (Eubacterium spp., Sneathia spp., Leptotrichia spp., Fusobacterium spp., Lachnobacterium spp., Clostridium spp.) were also isolated from more than 50% of patients. The most common HSV in patients with BV was HSV type 2 – 85%; a combination with human papillomavirus (HPV) was detected in 66.3% and a combination of different types of herpes viruses in 55%. Statistically significant high levels of cytokines were revealed in patients with RBV infected with HSV, compared to women with normal vaginal microbiocenosis: IL-1β – by 1.8 times, IL-6 – 1.7 times, TNF-α – 1.5 times (p&lt;0.001) and IL-8 – by 1.4 times, IL-4 – by1.4 times, IL-10 – by 1.6 times (P&lt;0.01).</p> <p><bold>Conclusion.</bold> In patients with RBV infected with HSV, there is a species diversity of microflora, including Staphylococcus spp. and a combination of herpes viruses and HPV in addition to anaerobic bacteria, increasing the level of cytokines. This justifies the need for complex treatment using not only antimicrobial drugs, but also immunomodulatory agents.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> В нaстоящее время отмечается высокая частотa рецидивов бактериального вагиноза (БВ) – более 50% в течение 3–6 месяцев и от 69 до 80% наблюдений в течение 12 месяцев после лечения.</p> <p><bold>Цель исследования:</bold> изучить особенности неспецифической защиты влагалища у пaциенток с рецидивирующим БВ (РБВ), инфицированным вирусом простого герпесa (ВПГ).</p> <p><bold>Методы.</bold> В исследование вошли 100 пациенток, разделенных на 2 группы: I (n=80) – с клиническим диaгнозом РБВ и ВПГ, II (n=20) – условно здоровые. Определяли бaктериальный состав в отделяемом из влагалища методом полимерaзной цепной реакции в реальном времени и содержание интерлейкина-1β (ИЛ-1β), ИЛ-2, -6, -8, интерферона-γ, фактора некроза опухоли-α (ФНО-α), ИЛ-4, -10 во влaгалищном секрете методом иммуноферментного анaлиза.</p> <p><bold>Результаты.</bold> Чаще всего выделяли Gardnerella vaginalis, Prevotella bivia и Atopobium vaginae (83,8%), у большинства пациенток обнаружены Megasphaera spp., Mobiluncus spp. (66,3%) и Staphilococcus spp. (32,5%), более чем у 50% пациенток выделены также и другие БВ-ассоциированные бактерии (Eubacterium spp., Sneathia spp., Leptotrichia spp., Fusobacterium spp., Lachnobacterium spp., Clostridium spp.). Наиболее часто встречаемым ВПГ у пациенток с БВ был ВПГ 2-го типа – 85%, выявлено сочетание с вирусом папилломы человека (ВПЧ) у 66,3% и сочетание различных типов вирусов герпеса у 55%. Выявлены статистически значимо более высокие показатели цитокинов у пациенток с РБВ, инфицированных ВПГ, по сравнению с женщинами с нормальным микробиоценозом влагалища: ИЛ-1β – в 1,8 раза; -6 – в 1,7; ФНО-α – в 1,5 раза (р&lt;0,001) и ИЛ-8 – в 1,4; -4 – в 1,4; -10 – в 1,6 раза (р&lt;0,01).</p> <p><bold>Заключение. </bold>У пациенток с РБВ, инфицировaнных ВПГ, наблюдается видовое рaзнообразие микрофлоры, включающее кроме анаэробных бактерий Staphilococcus spp. и сочетание вирусов герпеса и ВПЧ, повышение уровня цитокинов. Это обосновывает необходимость комплексного лечения с использованием не только антимикробных препаратов, но и средств иммуномодулирующего действия.</p></trans-abstract><kwd-group xml:lang="en"><kwd>bacterial vaginosis</kwd><kwd>relapse</kwd><kwd>herpes simplex virus</kwd><kwd>microbiota</kwd><kwd>immunity</kwd><kwd>cytokines</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>бактериальный вaгиноз</kwd><kwd>рецидив</kwd><kwd>вирус простого герпесa</kwd><kwd>микробиота</kwd><kwd>иммунитет</kwd><kwd>цитокины</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Coudray M.S., Madhivanan P. Bacterial vaginosis-A brief synopsis of the literature. Eur J.Obstet Gynecol Reprod Biol. 2020;245:143–48. Doi: 10.1016/j.ejogrb.2019.12.035.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Peebles K., Velloza J., Balkus J.E., et al. High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. Sex Transm Dis. 2019;46(5):304–11. Doi: 10.1097/OLQ.0000000000000972.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Ravel J., Moreno I., Simon C. Bacterial vaginosis and its association with infertility, endometritis, and pelvic inflammatory disease. Am J Obstet Gynecol. 2021;224(3):251–57. Doi: 10.1016/j.ajog.2020.10.019.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Tabatabaei N., Eren A.M., Barreiro L.B., et al. Vaginal microbiome in early pregnancy and subsequent risk of spontaneous preterm birth: a case-control study. BJOG. 2019;126(3):349–58. Doi: 10.1111/1471-0528.15299.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Muzny C.A., Laniewski P., Schwebke J.R., Herbst-Kralovetz M.M. Host-vaginal microbiota interactions in the pathogenesis of bacterial vaginosis. Curr Opin Infect Dis. 2020;33(1):59–65. Doi: 10.1097/QCO.0000000000000620.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Mtshali A., San J.E., Osman F., et al. Temporal Changes in Vaginal Microbiota and Genital Tract Cytokines Among South African Women Treated for Bacterial Vaginosis. Front Immunol. 2021;12:730986. Doi: 10.3389/fimmu.2021.730986.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Zhang T., Xue Y., Yue T., et al. Characteristics of aerobic vaginitis among women in Xi’an district: a hospital-based study. BMC. Womens Health. 2020;20(1):138. Doi: 10.1186/s12905-020-00997-5.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Qi W., Li H., Wang C., et al. Recent Advances in Presentation, Diagnosis and Treatment for Mixed Vaginitis. Front Cell Infect Microbiol. 2021;11:759795. Doi: 10.3389/fcimb.2021.759795.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Esber A., Vicetti Miguel R.D., Cherpes T.L., et al. Risk of bacterial vaginosis among women with herpes simplex virus type 2 infection: A Systematic Review and Meta-analysis. J Infect Dis. 2015;212(1):8–17. Doi: 10.1093/infdis/jiv017.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>James C., Harfouche M., Welton N.J., et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull. World Health Organ. 2020;98(5):315–29. Doi: 10.2471/BLT.19.237149.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Chen X., Lu Y., Chen T., Li R. The Female Vaginal Microbiome in Health and Bacterial Vaginosis. Front. Cell Infect Microbiol. 2021;11:631972. Doi: 10.3389/fcimb.2021.631972.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Mendling W., Palmeira-de-Oliveira A., Biber S,. Prasauskas V. An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review. Arch Gynecol Obstet. 2019;300(1):1–6. Doi: 10.1007/s00404-019-05142-8.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Jimenez N.R., Maarsingh J.D., Laniewski P., Herbst-Kralovetz M.M. Commensal Lactobacilli Metabolically Contribute to Cervical Epithelial Homeostasis in a Species-Specific Manner. mSphere. 2023;8(1):e0045222. Doi: 10.1128/msphere.00452-22.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Laniewski P., Herbst-Kralovetz M.M. Bacterial vaginosis and health-associated bacteria modulate the immunometabolic landscape in 3D-model of human cervix. NPJ Biofilms Microbiomes 2021;7(1):88. Doi: 10.1038/s41522-021-00259-8.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Johnston Ch., Magaret А., Yuhas К., et al. Association between genital herpes simpex virus type-2 shedding and presence of bacterial vaginosis-associated bacteria. Sex Transm Infect. 2017;93(Suppl. 2):A74–75. Doi: 10.1136/sextrans-2017-053264.188.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Masese L., Baeten J.M., Richardson B.A., et al. Incident herpes simplex virus type 2 infection increases the risk of subsequent episodes of bacterial vaginosis. J Infect Dis. 2014;209(7):1023–27. Doi: 10.1093/infdis/jit634.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Stoner K.A., Reighard S.D., Vicetti M.R.D., et al. Recalcitrance of bacterial vaginosis among herpes-simplex-virus-type-2-seropositive women. J Obstet Gynaecol Res. 2012;38(1):77–83. Doi: 10.1111/j.1447-0756.2011. 01697.x.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Petrina M.A.B., Cosentino L.A., Rabe L.K., Hillier S.L. Susceptibility of bacterial vaginosis (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin. Anaerobe. 2017;47:115–19. Doi: 10.1016/j.anaerobe.2017.05.005.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Ranjit E., Raghubanshi B.R., Maskey S., Parajuli P. Prevalence of Bacterial Vaginosis and Its Association with Risk Factors among Nonpregnant Women: A Hospital Based Study. Int J Microbiol. 2018;2018:8349601. Doi: 10.1155/2018/8349601.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Oh K.Y., Lee S., Lee M.S., et al. Composition of Vaginal Microbiota in Pregnant Women With Aerobic Vaginitis. Front Cell Infect Microbiol. 2021;11:677648. Doi: 10.3389/fcimb.2021.677648.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Kremleva E.A., Sgibnev A.V. Proinflammatory Cytokines as Regulators of Vaginal Microbiota. Bull Exp Biol Med. 2016;162(1):75–8. Doi: 10.1007/s10517-016-3549-1.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Martins B.C.T., Guimaraes R.A., Alves R.R.F., Saddi V.A. Bacterial vaginosis and cervical human papillomavirus infection in young and adult women: a systematic review and meta-analysis. Rev Saude Publ. 2023;56:113. Doi: 10.11606/s1518-8787.2022056004412.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Lin W., Zhang Q., Chen Y., et al. Changes of the vaginal microbiota in HPV infection and cervical intraepithelial neoplasia: a cross-sectional analysis. Sci Rep. 2022;12(1):2812. Doi: 10.1038/s41598-022-06731-5.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Ntuli L., Mtshali A., Mzobe G., et al. Role of Immunity and Vaginal Microbiome in Clearance and Persistence of Human Papillomavirus Infection. Front Cell Infect Microbiol. 2022;12:927131. Doi: 10.3389/fcimb.2022.927131.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Lin W., Zhang Q., Chen Y. et al. The prevalence of human papillomavirus and bacterial vaginosis among young women in China: a cross-sectional study. BMC. Women’s Health. 2021;21(1):409. Doi: 10.1186/s12905-021-01504-0.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Romero-Morelos P., Bandala C., Jimenez-Tenorio J., et al. Vaginosis-associated bacteria and its association with HPV infection. Med Clin (Barc). 2019;152(1):1–5. English, Spanish. Doi: 10.1016/j.medcli.2018.01.027.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Torcia M.G. Interplay among Vaginal Microbiome, Immune Response and Sexually Transmitted Viral Infections. Int J Mol Sci. 2019;20(2):266. Doi: 10.3390/ijms20020266.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Benyas D., Sobel J.D. Mixed Vaginitis Due to Bacterial Vaginosis and Candidiasis. J Low Genit Tract. Dis. 2022;26(1):68–70. Doi: 10.1097/LGT.0000000000000641.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Tortelli B.A., Lewis W.G., Allsworth J.E., et al. Associations between the vaginal microbiome and Candida colonization in women of reproductive age. Am. J. Obstet. Gynecol. 2020;222(5):471.e1–471.e9. Doi: 10.1016/j.ajog.2019.10.008.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Perez-Torralba C., Ruiz-Olivares M., Sanbonmatsu-Gomez S., et al. Aumento de las infecciones por virus del herpes simple tipo 1 y polimicrobianas del aparato genital, en la poblacion general de una ciudad media espanola (Increased infections by herpes simplex virus type 1 and polymicrobials of the genital tract, in the general population of a Spanish middle city). Rev Esp Quimioter. 2021;34(4):320–9. Spanish. Doi: 10.37201/req/004.2021.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Бебнева Т.Н., Шилов Б.В. Изменения экспрессии ряда генов и микробиома на фоне папилломавирусной инфекции у беременных женщин. Проблемы репродукции. 2019;25(6):105–11. [Bebneva T.N., Shilov B.V. Changes in the expression of a number of genes and the microbiome against the background of human papillomavirus infection in pregnant women. Reprod Probl. 2019;25(6):105–11. (In Russ.)]. Doi: 10.17116/repro201925061105.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Anahtar M.N., Byrne E.H., Doherty K.E., et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity. 2015;42(5):965–76. Doi: 10.1016/j.immuni.2015.04.019.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Garrett N., Mtshali A., Osman F., et al. Impact of point-of-care testing and treatment of sexually transmitted infections and bacterial vaginosis on genital tract inflammatory cytokines in a cohort of young South African women. Sex Transm Infect. 2021;97(8):555–65. Doi: 10.1136/sextrans-2020-054740.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Hruzevskyi О. The cytokine system’s status in bacterial dysbiosis and bacterial vaginosis. ScienceRise: Med Sci. 2020;3:360. Doi: 10.15587/2519-4798.2020.204094.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Marsden V., Donaghy H., Bertram K.M., et al. Herpes simplex virus type 2-infected dendritic cells produce TNF-α, which enhances CCR5 expression and stimulates HIV production from adjacent infected cells. J Immunol. 2015;194:4438–45. Doi: 10.4049/jimmunol.1401706.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Keller M.J., Huber A., Espinoza L., et al. Impact of Herpes Simplex Virus Type 2 and Human Immunodeficiency Virus Dual Infection on Female Genital Tract Mucosal Immunity and the Vaginal Microbiome. J Infect Dis. 2019;220(5):852–61. Doi: 10.1093/infdis/jiz203.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Дикке Г.Б., Суханов А.А., Кукарская И.И., Остроменский В.В. Иммуноопосредованные механизмы воспалительного ответа при сочетанных инфекциях нижнего отдела полового тракта у женщин. Акушерство, гинекология и репродукция. 2020;15(3):245–57. Doi: 10.17749/2313-7347/ob.gyn.rep.2021.209. [Dikke G.B., Sukhanov А.А., Kukarskaya I.I., Ostromensky V.V. Immune-mediated mechanisms of the inflammatory response in women with combined infections of the lower genital tract. Obstet Gynecol Reprod. 2020;15(3):245–57. (In Russ.)].</mixed-citation></ref></ref-list></back></article>
